When was Newleos founded?

Newleos was founded in 2009 and raised its 1st funding round 16 years after it was founded.

Where is Newleos located?

Newleos is headquartered in Boston, United States.

Is Newleos a funded company?

Newleos is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Feb 10, 2025.

When was the latest funding round of Newleos?

Newleos' latest funding was a $***** Series A round on Feb 10, 2025, with participation from 5 investors.

Where does Newleos rank among its competitors?

Newleos ranks 11th amongst 96 active competitors, of which 21 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was HMNC Brain Health, which secured $50M in Jun, 2026.

Who are the top competitors of Newleos?

Newleos' top competitors include Alto Neuroscience, Enveda and Vanda Pharmaceuticals. Among them, HMNC Brain Health secured the most recent funding round in June, 2026.

Newleos - 2026 Company Profile, Team, Funding & Competitors

Newleos is a series A company based in Boston (United States), founded in 2009 by Federico Bolognani. It operates as a Developer of oral small molecules for neuropsychiatric conditions treatment. Newleos has raised $93.5M in funding from Goldman Sachs Asset Management. The company has 96 active competitors, including 21 funded and 24 that have exited. Its top competitors include companies like Alto Neuroscience, Enveda and Vanda Pharmaceuticals.

Company Details

Developer of oral small molecules for neuropsychiatric conditions treatment. It focuses on neuropsychiatric mechanisms of action that aim to reduce side effects. Its molecules target GABAA-γ1, V1a, TAAR1 and GABAA-α5, with potential in treating anxiety and substance use disorders.

Key Metrics

Founded Year

2009

Location

Boston, United States

Stage

Series A

Total Funding

$93.5M in 1 round

Latest Funding Round

Series A, Feb 10, 2025, $*****

Investors

Goldman Sachs Asset Management & 4 more

Ranked

11^th among 96 active competitors

Similar Companies

Alto Neuroscience & 124 more

View Newleos' full profile

Newleos has raised a total funding of $93.5M over 1 round. Its latest funding round was a Series A round on Feb 10, 2025 for $*****. 5 investors participated in its latest round. Newleos has 5 institutional investors.

Here is the list of recent funding rounds of Newleos:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 10, 2025	4673980	Series A	6664026	5219722	1739450	6980490

Access funding benchmarks and valuations. Sign up today!

View details of Newleos's funding rounds and investors

The founders of Newleos is Federico Bolognani. David Donabedian is the CEO of Newleos.

Here are the details of Newleos' key team members:

Federico Bolognani: Chief Medical Officer and co-Founder of Newleos.
Contact Info: 1 email address

View details of Newleos's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Newleos include Alto Neuroscience, Enveda and Vanda Pharmaceuticals. Here is the list of Top 10 competitors of Newleos, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alto Neuroscience 2019, San Francisco (United States), Public	AI-driven drug discovery platform for neurological diseases based on patients biomarkers	$145M	Commodore Capital, Alpha Wave Global & 36 others	68/100
2nd	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 30 others	63/100
3rd	Vanda Pharmaceuticals 2003, Washington, DC (United States), Public	Developer of pharmaceutical products for treating CNS disorders	$33.5M	Domain Associates, MedImmune Ventures & 4 others	62/100
4th	Beckley Psytech 2019, Oxford (United Kingdom), Series B	Developer of rapid-acting psychedelic medicines for mental health disorders	$153M	ATAI, Noetic Psychedelic Fund & 27 others	62/100
5th	Seaport Therapeutics 2020, Boston (United States), Public	Developer of therapeutics to treat neuropsychiatric disorders	$325M	T. Rowe Price, Foresite Capital & 7 others	60/100
6th	Supernus Pharmaceuticals 2005, Rockville (United States), Public	Innovating CNS treatments, improving lives through neurological and psychiatric solutions	-	Abingworth, Westwicke & 6 others	59/100
7th	HMNC Brain Health 2010, Munich (Germany), Series B	Developer of targeted therapies for depression and other neuropsychiatric disorders	$41.5M	Maschmeyer Group, Kompernass & 10 others	55/100
8th	Reunion Neuroscience 2022, Toronto (Canada), Acquired	Developer of therapeutics for mental health conditions	$120M	MPM BioImpact, Novo Holdings & 7 others	54/100
9th	Neurovance 2011, Cambridge (United States), Acquired	Drug to modulate neurochemicals to treat Attention Deficit Hyperactivity Disorder .	$53M	GBS, Novartis Venture Fund & 3 others	53/100
10th	Reviva Pharmaceuticals 2006, San Jose (United States), Public	Develops therapeutic drugs for treatment of central nervous system	$49.1M	Lynx Financial	53/100
11th	Newleos 2009, Boston (United States), Series A	Developer of oral small molecules for neuropsychiatric conditions treatment	$93.5M	Longwood Fund, Arkin Holdings & 3 others	52/100